16th WCIRDC

World Congress Insulin Resistance
DIABETES & CARDIOVASCULAR DISEASE

November 29 – December 1, 2018
Hilton Universal City Hotel
Los Angeles, CA

Exploring New Frontiers In Metabolism – Tomorrow’s Clinical Science Today

www.WCIR.org
Welcome.

It is my pleasure to invite you to join us for the 16th Annual World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC), where the program activities fulfill the theme Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today. Since its inception, the Congress has become the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD) and metabolism. It provides an exclusive opportunity for practicing professionals, clinical and basic scientists, researchers and other clinicians to collaborate on emerging scientific principles and management strategies. The WCIRDC faculty consists of distinguished global experts who link research to clinical practice in a bench-to-bedside approach that is unique to this state-of-the-art program.

This year, we celebrate the life and scientific contributions of Dr. Gerald Reaven with a special session dedicated to his work entitled “The Metabolic Syndrome Revisited: A Salute to Gerald Reaven, MD,” chaired by Ralph DeFronzo, and featuring lectures on the mechanisms physiology and pathophysiology of insulin resistance, delivered by Peter Reaven, MD, and George King, MD, as well as Ralph DeFronzo, MD. In addition, we will honor the leadership and incredible scientific work of Philip E. Scherer, the recipient of the newly named Gerald M. Reaven Distinguished Leader in Insulin Resistance Award for his contribution to the development and understanding of the science and research of insulin resistance and diabetes. Dr. Scherer is a Professor in the Department of Internal Medicine at University of Texas Southwestern Medical Center and Director of Touchstone Diabetes Center in Dallas, Texas. His keynote lecture will be “The Central Role of Adipose Tissue for Metabolic Homeostasis and Systemic Insulin Sensitivity.”

In addition to these special sessions, attendees can participate in workshops, Meet the Experts Sessions & clinical lectures, all of which provide an opportunity to personally interact with global leaders in an intimate setting. Every session includes a unique feature of the Congress: experts’ commentary on the clinical implications of basic and scientific research.

I look forward to having you join us for this exciting program in Los Angeles.

Best regards,

Yehuda Handelsman, MD
Chair & Program Director
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 16th year, is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance. This unique and exciting meeting links basic research to clinical practice under the theme, Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

For almost two decades, the WCIRDC has brought researchers, physicians, and healthcare professionals together for a distinctive international program that bridges the latest developments from bench to bedside. “I heard it first at the Congress” has become an often-heard refrain from WCIRDC attendees, many of whom return year after year. The Congress not only provides a forum for researchers to present their latest data — on everything from biomarkers & new physiologic insights to new therapies — it also offers attendees a unique opportunity to interact with the distinguished global faculty in a collaborative experience.

**PROGRAM DESCRIPTION**

Together, experts, young researchers, and clinicians can explore the newest findings on metabolic diseases and the development of future therapeutic modalities.

Since Dr. Gerald Reaven’s pioneering work crystallized the relationship between insulin resistance, diabetes, and CVD, the Congress’ focus has expanded to the fat cell, lipids, the kidney, the brain, bone, energy metabolism, inflammation, CVD complications, and cancer. Along with obesity, diabetes, and CVD, Congress sessions address atherosclerosis, hypertension, and hypercoagulation, as well as pharmaceutical interventions such as incretins, SGLT2 inhibitors, and PCSK9 inhibitors, to name a few. The goal is to discuss the state-of-the-art in pathophysiology and to develop appropriate comprehensive clinical management strategies.

For primary care clinicians, the Congress will feature a series of workshops and “Meet the Expert” panels addressing the clinical management of kidney disease, diabetes, obesity, lipids, the high risk CVD patient, and more. To make research topics relevant to clinical medicine, there will be commentaries on the clinical implications by recognized experts. The Congress’ intimate setting promotes a lot of personal contact between participants and the faculty wherein everyone learns from the free flow of questions and personal observations.

The Congress attracts state-of-the-art abstracts from around the globe. These abstracts will be published in *Endocrine Practice* (ISSN: 1530-891X). This peer-reviewed journal is published twelve times a year and is the official journal of the American Association of Clinical Endocrinologists (AACE).

Typically, articles about the meeting are published in several medical journals, including *Endocrine Practice, Metabolism, The Journal of Diabetes, and Diabetes*. Typically, articles about the meeting are published in several medical journals, including *Endocrine Practice, Metabolism, The Journal of Diabetes, and Diabetes*.

**PROGRAM OBJECTIVES**

- Evaluate the extent of vascular disease in diabetes and cardiometabolic syndrome
- Evaluate the extent of macro- and microvascular disease in diabetes and obesity
- Provide comprehensive management of diabetes, addressing obesity, hypertension, and dyslipidemia as well as glucose
- Discuss the role of incretins in the management of obesity, diabetes, and their complications
- Evaluate the evidence supporting the use of SGLT2 inhibitors and GLP1 RAs to reduce cardiovascular mortality in patients with T2D
- Describe the role of PCSK9 and CETP in lipid elevations and their potential contributions to vascular disease
- Discuss the mechanism of action of PCSK9 inhibitors and CETP inhibitors and their impact on CVD
- Discuss changes in lipid management guidelines
- Describe obesity management based on a complications-centric model
- Recognize the multi-hormonal pathophysiology of obesity, its relationship to food addiction, and its potential target for management
- Explain the pathophysiology and complications of fatty liver disease and its relationship to diabetes and CVD
- Describe the pathogenesis of liver and muscle insulin resistance and the role of adipose tissue mitochondria in promoting hyperglycemia
- Evaluate the impact on clinical practice of new CV outcome trials in patients with diabetes, including CANVAS, LEADER, SUSTAIN 6, and EMPA-REG
- Evaluate the impact on clinical practice of lipid CV outcome trials, including IMPROVE-IT, FOURIER, REDUCE-IT, ODYSSEY-Outcomes
- Implement best practices for the management of CHF

**TARGET AUDIENCE**

This educational initiative is designed for: cardiologists, endocrinologists, gastroenterologists, oncologists, internists, diabetologists, OBGYNs, pediatricians, dietitians, nurse practitioners, pharmacists, and any other health care professionals who are interested in insulin resistance, diabetes, obesity, cardiovascular disease, and multiple metabolic mechanisms’ effects on health and society, as well as on potential treatment and prevention.
7:00am – 8:00am  Registration & Continental Breakfast at Exhibit Hall
8:00am – 8:10am  Welcome & Introduction  Yehuda Handelsman, MD/ Chair

SESSION #1  INFLAMMATION, CVD & CHF IN DM
Chairs: Robert R. Henry, MD • George Grunberger, MD
8:10am  CME Questions
8:15am  Dietary Saturated Fats vs Carbohydrates Impact on CVD Risk  Ronald M. Krauss, MD
8:35am  State-of-the-Art: CHF in Diabetes 2018 Update  Javed Butler, MD
9:00am  Has CANTOS Nailed the Inflammatory Hypothesis of Atherosclerosis?  Sanjay Kaul, MD
9:25am  Anti-Inflammatory Therapy for Cardiovascular Disease and Diabetes  Brendan M. Everett, MD
9:45am – 10:05am  Q+A Panel Discussion & Clinical Implications
10:05am – 10:35am  Refreshment Break at Exhibit Hall

SESSION #2  DIABETES
Chairs: Bart Staels, PhD • Derek LeRoith, MD, PhD
10:35am  We Can Stem the Diabetes Epidemic and Do It Adroitly; Here’s How  W. Timothy Garvey, MD
10:55am  Is there a Case for the Circadian Syndrome?  Paul Zimmet, AO, PhD
11:15am  Control of Endogenous Glucose Production  Richard N. Bergman, PhD
11:35am  The New Biology of Type 2 Diabetes  Gerald I. Shulman, MD, PhD
12:00pm – 12:20pm  Q+A Panel Discussion & Clinical Implications

SESSION #3  THE METABOLIC SYNDROME REVISITED: A SALUTE TO GERALD REAVEN, MD
Chairs: Ralph A. DeFronzo, MD • Peter J. Grant, MD
1:30pm  Glucose Control and Vascular Disease: Is the Glass Half Empty or Half Full?  Peter Reaven, MD
1:55pm  Insulin Resistance in T2DM: Whole Body, Organ, Cellular, and Molecular Pathogenesis  Ralph A. DeFronzo, MD
2:20pm  Insulin Resistance: Molecular and Cardiovascular Implications  George L. King, MD
2:45pm  Insulin Resistance is a Physiologic Defense Against Metabolic Stress  Marc Prentki, PhD
3:10pm – 3:30pm  Q+A Panel Discussion & Clinical Implications
3:30pm – 4:00pm  Refreshment Break at Exhibit Hall

CONCURRENT SESSIONS  MEET THE EXPERT
4:00pm – 4:50pm
• Daniel Einhorn, MD  Diabetes Guidelines 2019 - A Guide for the Perplexed
• Mikhail Kosiborod, MD  CVD in Diabetes
• Ralph A. DeFronzo, MD  Insulin Resistance & Complications
• Yehuda Handelsman, MD  Lipids, Metabolism & the Heart

SESSION #4  CVB MANAGEMENT TODAY AND TOMORROW
Chairs: Robert Chilton, DO • Alan Sinaiko, MD
5:00pm  New CV Outcome Trials  Mikhail Kosiborod, MD
5:30pm – 6:10pm  DEBATE: GLUCOSE MANAGEMENT HAS LITTLE IMPACT ON CVD IN DM
YES  Darren McGuire, MD
NO  George Grunberger, MD
6:10pm – 6:30pm  Q+A Panel Discussion & Clinical Implications & Post-CME Questions

6:30PM – 7:30PM WELCOME AND POSTERS RECEPTION

DINNER SYMPOSIUM  CME
CHF IN DM THE NEXT FRONTIER- DO SGLT2I HAVE A ROLE IN MANAGEMENT & PREVENTION
• Epidemiology of CHF in Diabetes Differentiating HFrEF and HfPEF  Bıyıkem Bozkurt, MD, PhD
• The Role of the Kidney in CHF: The Cardio-Renal Syndrome  Matthew R. Weir, MD
• Diabetes CVOT Impact on CHF in Diabetes  Mikhail Kosiborod, MD
• The Contemporary Approach to the Management of CHF in DM & Non-DM  Robert Chilton, DO
Panel and Q&A — The Future of the Diagnosis and Management of CHF  
Supported by an Education Grant from: ASTRAZENECA
6:00am – 8:00am  Registration & Coffee at Exhibit Hall

6:45am – 7:45am  PRODUCT THEATER  Non CME  Full Breakfast will be Provided
Jardiance® (emagliflozin) tablets: Evolving Clinical Development
Supported By: BOVIERINGER INGLEHEIM / LILLY USA

7:50am – 8:00am  Summary of First Day
Zachary T. Bloomgarden, MD

SESSION #5  LIPIDS MANAGEMENT GOALS & COMPLICATIONS
Chairs: Ronald M. Krauss, MD  •  Paul S. Jellinger, MD
8:00am  Pre CME Questions
8:05am  Lessons From the PCSK9 Outcome Trials
Normal E. Lepor, MD

8:25am – 9:05am  DEBATE: THE BIG LDL DEBATE FURTHER TREATMENT BENEFIT:
A) MOSTLY WHEN BASELINES LDL-C > 100; B) THE LOWER GOAL LDL-C THE BETTER
YES / NO Jennifer G. Robinson, MD
NO / YES Sergio Fazio, MD, PhD

9:05am  Understanding How Statins Cause Increased Risk of Diabetes
Joshua W. Knowles, MD, PhD

9:25am – 9:45am  Q+A Panel Discussion & Clinical Implications

SESSION #6  DIABETES & CVD IN THE DEVELOPING YEARS
Chairs: Paul Zimmet, AO, PhD  •  Mikhail Kosiborod, MD
9:45am  Obesity and Cardiovascular Disease in Children and Adolescents
Stephen R. Daniels, MD, PhD
10:05am – 10:35am  Refreshment Break at Exhibit Hall

10:35am  Early Treatment of Youth Onset T2D with Metformin or Insulin Failed to Restore Beta Cell Function:
Lessons from the RISE-Pediatric Medication Study
Sonia Caprio, MD
10:55am  Relation of Childhood Cardiovascular Risk Factors to Adult Cardiovascular Disease
Alan Sinaiko, MD
11:15am – 11:30am  Q+A Panel Discussion & Clinical Implications

SESSION #7  INSULIN RESISTANCE AND DIABETES
Chairs: Daniel Einhorn, MD  •  Tracey L. McLaughlin, MD
11:30am  Insulin Resistance in Health and Disease
Peter J. Grant, MD
11:50am  Adapting to InsulinResistance in Obesity: Role of Insulin Secretion and Clearance
Sun H. Kim, MD
12:10pm  The Relationship of Diabetes, Metabolism & Aging
Derek LeRoith, MD, PhD
12:30pm  FGF1 – Resetting Diabetes
Ronald M. Evans, PhD
12:50pm – 1:05pm  Q+A Panel Discussion & Clinical Implications

SESSION #8  PERSONALIZED MEDICINE – APPETITE THE GUT & THE MICROBIOME
Chairs: Samuel Klein, MD  •  Sonia Caprio, MD
2:00pm  Bile Acids: Signaling Molecules Connecting the Gut to the Liver in Metabolic Control
Bart Staal, PhD
2:20pm  Personalized Nutrition for Diabetes Based on Gut Microbiome and Clinical Data
Eran Segal, PhD
2:40pm  TMAO Update
Ronald M. Krauss, MD
3:00pm  Mechanisms Regulating Appetite and Weight in Humans: An Update
Christos Mantzoros, MD, DSc, PhD
3:20 pm – 3:40pm  Q+A Panel Discussion & Clinical Implications

SESSION #9  THE STATE OF DIABETES & CVD
Chairs: Christian Mende, MD  •  Phillip Levy, MD
3:40pm  The State of Obesity and Diabetes in China and Impact on CVD
Guang Ning, MD, PhD
4:00PM - 4:30PM  Refreshment Break at Exhibit Hall
4:30pm  Diabetes with ASCVD in Latin America: Is it all the same?
Jaime A. Davidson, MD
4:50pm  Q+A Panel Discussion & Clinical Implications

SESSION #10  WHAT’S IN THE PIPELINE?  Non CME
Chairs: Ralph A. DeFronzo, MD  •  Christos Mantzoros, MD, DSc, PhD
5:00pm  AZ / MedImmune
Booz Hirshberg, MD
5:15pm  Gilead
C. Stephen Djugos, MD
5:30pm  Lilly
Leonard C. Glass, MD
5:45pm  Novo Nordisk
Todd Hobbs, MD
6:00pm  Amgen
Scott M. Wasserman, MD
6:15pm – 6:30pm  Q+A Panel Discussion & Clinical Implications & Post-CME Questions

6:30PM – 8:00PM  ABSTRACT – ORAL PRESENTATION
Zachary T. Bloomgarden, MD Chair  •  Philip Levy, MD  •  Daniel Einhorn, MD  •  George Grunberger, MD
Abstracts are published in “Endocrine Practice”, the official journal of the AACE  |  Editor in Chief: Derek LeRoith, MD, PhD
SATURDAY, DECEMBER 1, 2018

SESSION #11 MANAGEMENT OF DM & CVD
Chairs: Yehuda Handelsman, MD • Peter J. Grant, MD

8:00am – 8:05am Pre CME Questions
8:05am BRAVO – At Last, a Dynamic Risk Engine for America
8:25am New ADA/EASD Practice Recommendations
8:45am ACC/AHA Lipids & ASCVD Guidelines 2018 Update
9:05am – 9:25am Q+A Panel Discussion & Clinical Implications

SESSION #12 FAT OBESITY & METABOLISM
Chairs: Vivian A. Fonseca, MD • W. Timothy Garvey, MD

AWARD PRESENTATION
By: Richard E. Pratley, MD
09:25am “Gerald Reaven Distinguished Leader in Insulin Resistance”

KEY NOTE
9:55am Are There Clinically Important Weight Loss-Independent Metabolic Benefits of Gastrointestinal Bypass Surgery?
10:15am - 10:35am Refreshment Break at Exhibit Hall
10:35am Sex and the Fat Cell
10:55am Obesity & Insulin Resistance in T1D - Clinical Implications
11:15am – 11:35am Q+A Panel Discussion & Clinical Implications

SESSION #13 CONTEMPORARY APPROACH TO NAFLD/NASH
Chairs: Jaime A. Davidson, MD • Christos Mantzoros, MD, DSc, PhD

11:35am 2018 Diagnostic Tools for Fatty Liver Disease and NASH
11:55am An Overview of Medications for NASH
12:15pm – 12:30pm Q+A Panel Discussion & Clinical Implications

SESSION #14 THE KIDNEY & THE HEART
Chairs: Zachary T. Bloomgarden, MD • Daniel Einhorn, MD

1:30pm Obesity, Insulin Resistance and Kidney Disease
1:50pm The Cardiorenal Syndrome
2:10pm – 2:50pm DEBATE: SHOULD PATIENTS WITH DIABETES & ESTABLISHED CARDIOVASCULAR DISEASE GET AN SGLT2i OR GLP1-RA?
GLP1-RA
SGLT2i
Mansoor Husain, MD
Sunder Mudaliar, MD
2:50pm The Fatty Kidney
3:10pm The Fatty Heart
3:30pm – 4:00pm Q+A Panel Discussion & Clinical Implications & CME Post Questions

CONCURRENT SESSIONS
4:05pm – 5:00pm CLINICAL WORKSHOPS

• Diabetes
  • Lipids
  • CHF
  • Hypertension

5:00pm Adjourn
FACULTY 2018

Yehuda Handelman, MD
FAC, FNLA, MACE Chair
Chair & Program Director
Medical Director & Principal Investigator
Metabolic Institute of America
Chair & Founder, International Committee for Insulin Resistance
Chair & Founder
International Lipid Forum
Torrance, California

Richard N. Bergman, PhD
Alfred Joy Feinstein Chair in Diabetes Research
Professor, Department of Biomedical Sciences, Cedars-Sinai
Director, Sports Spectacular Diabetes and Obesity Wellness and Research Center (SSDOWRC)
Professor-in-Residence, Department of Medicine, UCLA
Los Angeles, California

Zachary T. Bloomgarden, MD
MACE
Clinical Professor
Department of Medicine
Icahn School of Medicine at Mount Sinai
Editor, The Journal of Diabetes New York, New York

Biykem Baskurt, MD, PhD, FACC, FAHA, FHPSA, FACP
Professor of Medicine
The Mary and Gordon Cain Chair W.A. “Tex” and Deborah Mancrief, Jr., Chair
Medicine Chief and Medical Care Line Executive, DeBakey VA Medical Center
Director, Winters Center for Heart Failure Research
Associate Director, Cardiovascular Research Institute
Boyle College of Medicine
Houston, Texas

Javed Butler, MD, MPH, MBA
Patrick A. Lehan
Professor of Medicine
Professor of Physiology
Chairman, Department of Medicine
University of Mississippi Medical Center
Jackson, Mississippi

Sonja Caprio, MD
Professor of Pediatric Endocrinology
Yale University School of Medicine
New Haven, Connecticut

Robert J. Chilton, DO, FACC
Professor of Medicine
Department of Medicine
Division of Cardiology
The University of Texas Health Science Center
San Antonio, Texas

David A. D’Alessio, MD
Professor of Medicine
Chief, Division of Endocrinology, Metabolism and Nutrition
Associate Director, Duke Molecular Physiology Institute
Durham, North Carolina

Stephen R. Daniels, MD, PhD
Chair, Department of Pediatrics
University of Colorado
School of Medicine
Pediatrician-in-Chief
Children’s Hospital Colorado
Denver, Colorado

Jaime A. Davidson, MD
FACP, MACE
Clinical Professor of Medicine
Division of Endocrinology and Metabolism
Touchstone Diabetes Research Center
The University of Texas Southwestern Medical Center
Dallas, Texas

Ralph A. DeFranzo, MD
Professor of Medicine
Chief, Diabetes Division
University of Texas Health Science Center at San Antonio (UTHSCSA)
Deputy Director
Texas Diabetes Institute
San Antonio, Texas

C. Stephen Djeujo, MD
(Non-CME Speaker)
Senior Director, Clinical Research
Liver Disease Therapeutic Area
Gilead Sciences
Foster City, California

Daniel Einhorn, MD, FACP, FACE
President
Diabetes and Endocerine Associates
Medical Director, Scripps Whittier Diabetes Institute
Clinical Professor of Medicine
University of California, San Diego
Past President, AACE
Past President, ACE
La Jolla, California

Ronald M. Evans, PhD
Professor and Director
Gene Expression Laboratory
Howard Hughes Medical Institute
Salk Institute for Biological Studies
La Jolla, California

Brendan M. Everett, MD, MPH
Director, General Inpatient Cardiology Service
Bingham and Women’s Hospital
Assistant Professor
Harvard Medical School
Boston, Massachusetts

Sergio Fazio, MD, PhD
The William and Sanja Connor Chair of Preventive Cardiology
Professor of Medicine and Physiology & Pharmacology
Director, Center for Preventive Cardiology
Knight Cardiovascular Institute
Oregon Health & Science University
Portland, Oregon

Vivian A. Fonseca, MD, FRCP
Professor of Medicine & Pharmacology
Assistant Dean for Clinical Research
Tulsa Tulane Alumni Chair in Diabetes
Chief, Section of Endocrinology
Tulane University
Health Sciences Center
New Orleans, Louisiana

W. Timothy Garvey, MD
Butterworth Professor & Chair
Department of Nutrition Sciences
GRECC Investigator and Staff Physician
Birmingham VA Medical Center
Director, UAB Diabetes Research and Training Center
Birmingham, Alabama

Leonard C. Glass, MD, FACE
(Non-CME Speaker)
Sr. Medical Director
Diabetes Clinical Development Design Hub
Lilly Research Laboratories
Eli Lilly & Company
Indianapolis, Indiana

Peter J. Grant, MD, FMedSci
Professor of Medicine and Consultant Physician
University of Leeds/Leeds Teaching Hospitals NHS Trust
Leeds Institute of Cardiovascular and Metabolic Medicine
LIGHT Laboratories
Leeds, United Kingdom

George Grunberger, MD
FACP, FACE
Chairman, Grunberger Diabetes Institute, Clinical Professor
Professor of Medicine
University of California, San Diego
Past President, AACE
Past President, ACE
La Jolla, California

Robert R. Henry, MD
Professor of Medicine
Department of Endocrinology & Metabolism
Veterans Affairs Healthcare System
Metabolism & Diabetes Chief, Section of Endocrinology & Metabolism
Baylor College of Medicine
Houston, Texas

Robert R. Henry, MD
Professor of Medicine
University of California, San Diego
Chief, Section of Endocrinology
Co-Director, Division of Endocrinology & Metabolism
La Jolla, California

Paul S. Jelleting, MD, MACE
Professor of Clinical Medicine
University of Miami Miller School of Medicine
The Center for Diabetes & Endocrine Care
Past President, AACE & ACE
Hollywood, Florida

Sanjay Kaul MD, FACC, FAHA
Professor of Medicine
Division of Cardiology
Cedars-Sinai Medical Center
David Geffen School of Medicine at UCLA
California

Todd Hobbs, MD
(Non-CME Speaker)
Senior Medical Director, Global Non-CME
Gilead Sciences
Liver Disease Therapeutic Area
Senior Director, Clinical Research
C. Stephen Djedjos, MD
San Diego, California

Sun H. Kim, MD, MS
Associate Professor of Medicine
Division of Endocrinology & Metabolism
Stanford University School of Medicine
Stanford, California

George L. King, MD
Chief Scientific Officer, Joslin Diabetes Center
Professor of Medicine and Ophthalmology
Harvard Medical School
Boston, Massachusetts

Samuel Klein, MD
William H. Danforth Professor of Medicine and Nutritional Science
Director, Center for Human Nutrition
Chief, Division of Geriatrics & Nutritional Science
Washington University School of Medicine
St. Louis, Missouri

Joshua W. Knowles, MD, PhD
FAHA, FACC
Assistant Professor of Medicine
Division of Cardiovascular Medicine
Stanford University
Chief, Translational Medicine
The FII Foundation
Stanford, California
ACCREDITATION INFORMATION. You can earn up to 27 credits. This activity was planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education through the joint providership of PESI Inc. and the Metabolic Endocrine Education Foundation (MEEF). PESI Inc. is accredited by the ACCME to provide continuing medical education for physicians.

AMA PRA Designation Statement The PESI Inc. designated this live activity for a maximum of 27 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

International CME International Physicians are formally eligible for AMA PRA Category 1 Credit™.

Physician Assistants AAPA accepts Category 1 credit from AOACCME, Prescribed credit from AAFP, and AMA PRA Category 1 Credit™ for the PRA from organizations accredited by ACCME. Nurses For the purpose of recertification, the American Nurses Credentialing Center accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CA Nurses Aspen CME Services is approved by the California Board of Registered Nursing, provider number CEP14739, designated the 16th WCIRDC for approximately xx contact hours.

Pharmacists For the purpose of recertification, the American Council of Pharmacy Education accepts AMA PRA Category 1 Credit™ issued by organizations accredited by the ACCME (Accreditation Council for Continuing Medical Education) for attendance at structured learning activities.

CDE The National Certification Board for Diabetes Educators recognizes courses sponsored by PESI Inc. as approved ACCME provider. This course qualifies for 27 continuing education hours.

Registered Dieticians For the purpose of recertification the Commission on Dietetic Registration recognizes courses accredited with AMA PRA Category 1 Credit™.

Satisfactory Completion for credits All attendees must have completed and turned in a course attendance/evaluation form prior to leaving the conference. Each session claimed for credit must be attended in its entirety.

PROGRAM COMMITTEE

Yehuda Handelsman, MD, Chair • Zachary T. Bloomgarden, MD • Sonia Caprio, MD • Jaime Davidson, MD • Ralph A. DeFronzo, MD Daniel Einhorn, MD • Vivian A. Fonseca, MD • W. Timothy Garvey, MD • Robert R. Henry, MD • Samuel Klein, MD • Mikhail N. Kosiborod, MD Ronald M. Krauss, MD • Derek LeRoith, MD, PhD • Philip Levy, MD • Christos Mantzoros, MD, DSc • Tracey L. McLaughlin, MD Christian W. Mende, MD • Richard E. Pratley, MD • Arun J. Sanyal, MBBS, MD • Bart Staels, PhD • Adrienne Stevens, EdD • Renee S. Asp, BS

The International Committee for Insulin Resistance Gratefully Acknowledges the Education Support of

PREMIER EDUCATOR
AstraZeneca

MAJOR EDUCATOR
Lilly USA, LLC
Merck

EDUCATOR
Amarin
Novo Nordisk
The 16th Annual World Congress on Insulin Resistance, Diabetes & CVD (WCIRDC) will be held at the prestigious Hilton Universal City Hotel. The majestic Hilton Hotel is situated on a high hill above the Los Angeles entertainment district, near Universal Studios Hollywood and City Walk. The hotel is located a block from the main entrance of Universal Studios Hollywood, and is also a 3.5-mile drive to Pantages Theatre for Broadway shows. This 24-story hotel offers upscale rooms with panoramic views of the Hollywood Hills and Universal Studios.

Hilton Universal City Hotel
555 Universal Hollywood Drive Universal City, CA 91608

To reserve a room at our special rate of $214 a night for conference participants and their guests call 818.506.2500 visit www.wcir.org/accomodations

Please reference the group name: WCIRDC

Rooms will be available on a first-come basis, and will be available until all are filled. Group room rates will be available three (3) days prior to and three (3) days after the event date. If you need special accommodations or if you have any questions about access to any of our activities, please contact the meeting organizers at 818 342 1889 or info@tmioa.com

Corporate Opportunities & Exhibit Space Are Still Available
Don’t miss the opportunity to be part of 16th WCIRDC
Showcase your products, service and technologies!
Reach out to the most influential leaders and decision-makers in the field
Meet with globally-recognized medical leaders, clinicians and scientists, who will present and share their knowledge
WCIRDC will dedicate an area, separate form the education program, where your company will be able to exhibit products, equipment and services

info@tmioa.com | 818.342.1889 | www.wcir.org

Save the Date • 17th WCIRDC • December 5 – 7, 2019
ATTENDANCE IS LIMITED!

Register online: www.wcir.org/registration
Email us: info@tmioa.com By phone 818 342-1889

Registration Fee Includes: CME credit, course materials, workshops, breakfast, lunch, refreshment breaks and welcome reception.

Cancellation Policy: A full refund will be given if written notice of cancellation is received by September 1st, 2018. A $75 cancellation fee will be charged for cancellation between September 2nd and November 1st, 2018. After November 1st there will be NO REFUND. We encourage participation by all individuals. If you have a disability, please notify us in writing of any special requirements to help us serve you better.

All Members of Participating Organizations Qualify for a Discount on Registration
Please email info@tmioa.com or call 818 342 1889 to receive a coupon code

PARTICIPATING ORGANIZATIONS

- American Academy of Physician Assistants (AAPA)
- American Association of Clinical Endocrinologists (AACE)
- American Association of Diabetes Educators (AADE)
- American Association for the Study of Liver Diseases (AASLD)
- American Board of Obesity Medicine (ABOM)
- American College of Nutrition (ACN)
- American Diabetes Association (ADA)
- American Gastroenterological Association (AGA)
- American Society of Endocrine Physician Assistants (ASEPA)
- American Society of Hypertension (ASH)
- American Society for Nutrition (ASN)
- American Society of Preventive Oncology (ASPO)
- Androgen Excess & PCOS Society (AE-PCOS)
- Canadian Association of Gastroenterology (CAG)
- Canadian Society of Endocrinology and Metabolism (CSEM/SCEM)
- European Association for the Study of the Liver (EASL)
- European Society of Cardiology (ESC)
- Familial Hypercholesterolemia (FH) Foundation
- International Academy of Cardiology (IAC)
- International Association for the Study of Obesity (IASO)
- Israel Endocrine Society (IES)
- Joslin Diabetes Center
- New Cardiovascular Horizons (NCVH)
- Pacific Lipid Association (PLA)
- Pediatric Endocrine Society (PES)
- Society for Endocrinology
- World Obesity Federation

Jointly Provided by:

[Logos of various organizations]

MEDIA PARTNERS

[Logos of various media partners]

The International Committee for Insulin Resistance Gratefully Acknowledges the Corporate Support of

[SAPPHIRE LEVEL]

AMGEN

[Logos of corporate sponsors]

[LOGO]

[LOGO]

[LOGO]

[LOGO]

[LOGO]

[LOGO]

[LOGO]
Metabolic Endocrine Education Foundation
18372 Clark Street #212, Tarzana, CA 91356

Save The Date
17th WCIRDC
Dec 5–7, 2019
CALIFORNIA

Save The Date
16th WCIRDC
November 29 - December 1, 2018
Hilton Universal City Hotel, Los Angeles, CA

USE COUPON CODE “BROCHURE” AND SAVE 10% OFF REGISTRATION
Email us: info@tmioa.com | By phone: 818-342-1889

Cancellation Policy: A full refund will be given if written notice of cancellation is received by September 1, 2018.
A $75 cancellation fee will be charged for cancellation between September 2, 2018 and November 1, 2018. After November 1, 2018 there will be NO REFUND.
Cancellations must be submitted via e-mail to info@tmioa.com or by phone at 818-342-1889.

For Additional Information on
SUPPORT · REGISTRATION · ACCOMODATION · EXHIBIT
818.342.1889 | 818.342.1538 | info@tmioa.com

www.wcir.org